James Loerop - 01 Feb 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Business Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
01 Feb 2023
Net transactions value
$0
Form type
4
Filing time
03 Feb 2023, 16:01:21 UTC
Previous filing
01 Feb 2022
Next filing
10 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +11,250 11,250 01 Feb 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Employee Stock Option (Right to Buy) Award $0 +105,000 $0.000000 105,000 01 Feb 2023 Common Stock 105,000 $16.97 Direct F2
transaction ACRS Restricted Stock Units Award $0 +30,000 $0.000000 30,000 01 Feb 2023 Common Stock 30,000 Direct F1, F3
transaction ACRS Restricted Stock Units Options Exercise $0 -11,250 -25% $0.000000 33,750 01 Feb 2023 Common Stock 11,250 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
F3 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
F4 The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.